Last reviewed · How we verify
RedHill Biopharma Limited — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
4 Phase 3
1 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| RHB-104 | RHB-104 | phase 3 | Antibiotic combination | Mycobacterium avium subspecies paratuberculosis (MAP) | Gastroenterology / Immunology | |
| RHB-102 | RHB-102 | phase 3 | Gastric motility agent | Ghrelin receptor | Gastrointestinal | |
| RHB-105 | RHB-105 | phase 3 | Antiviral combination therapy | Infectious Diseases | ||
| Rifamycin SV MMX | Rifamycin SV MMX | phase 3 | Ansamycin antibiotic | Bacterial RNA polymerase | Gastroenterology / Infectious Disease |
Therapeutic area mix
- Gastroenterology · 1
- Gastroenterology / Immunology · 1
- Gastroenterology / Infectious Disease · 1
- Gastrointestinal · 1
- Infectious Diseases · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Beijing 302 Hospital · 1 shared drug class
- Brooke Army Medical Center · 1 shared drug class
- CCTU · 1 shared drug class
- Casa Sollievo della Sofferenza IRCCS · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- HK inno.N Corporation · 1 shared drug class
- Halmstad County Hospital · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for RedHill Biopharma Limited:
- RedHill Biopharma Limited pipeline updates — RSS
- RedHill Biopharma Limited pipeline updates — Atom
- RedHill Biopharma Limited pipeline updates — JSON
Cite this brief
Drug Landscape (2026). RedHill Biopharma Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/redhill-biopharma-limited. Accessed 2026-05-16.